Key result
Post-MI wearable ECG detects paroxysmal atrial tachycardia in 56%, linked to lower beta-blocker use.
Why the study?
Acute myocardial infarction can be associated with serious new-onset arrhythmias, and prolonged ECG monitoring may prevent devastating outcomes, motivating investigation of arrhythmia incidence using a patch-type wearable device.
What is the incidence of arrhythmias detected by an 11-day wearable ECG patch device in patients following myocardial infarction?
Cohort (n=71)
No
What is the incidence of arrhythmias detected by an 11-day wearable ECG patch device in patients following myocardial infarction?
An 11-day wearable ECG patch frequently detects subclinical arrhythmias, including paroxysmal atrial tachycardia, in patients recovering from myocardial infarction.
Wearable ECG post-MI may inform arrhythmia surveillance; leaves open whether detection should guide beta-blocker therapy or affect outcomes.
BACKGROUND Acute myocardial infarction may be associated with new-onset arrhythmias. Patients with myocardial infarction may manifest serious arrhythmias such as ventricular tachyarrhythmias or atrial fibrillation. Frequent, prolonged electrocardiogram (ECG) monitoring can prevent devastating outcomes caused by these arrhythmias. OBJECTIVE We aimed to investigate the incidence of arrhythmias in patients following myocardial infarction using a patch-type device—AT-Patch (ATP-C120; ATsens). METHODS This study is a nonrandomized, single-center, prospective cohort study. We evaluated 71 patients who had had a myocardial infarction and had been admitted to our hospital. The ATP-C120 device was attached to the patient for 11 days and analyzed by 2 cardiologists for new-onset arrhythmic events. RESULTS One participant was concordantly diagnosed with atrial fibrillation. The cardiologists diagnosed atrial premature beats in 65 (92%) and 60 (85%) of 71 participants, and ventricular premature beats in 38 (54%) and 44 (62%) participants, respectively. Interestingly, 40 (56%) patients showed less than 2 minutes of sustained paroxysmal atrial tachycardia confirmed by both cardiologists. Among participants with atrial tachycardia, the use of β-blockers was significantly lower compared with patients without tachycardia (70% vs 90%, P=.04). However, different dosages of β-blockers did not make a significant difference. CONCLUSIONS Wearable ECG monitoring patch devices are easy to apply and can correlate symptoms and ECG rhythm disturbances in patients following myocardial infarction. Further study is necessary regarding clinical implications and appropriate therapies for arrhythmias detected early after myocardial infarction to prevent adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Kwun et al. (2021) conducted a cohort in Myocardial infarction (n=71). AT-Patch (ATP-C120; ATsens) wearable ECG monitoring was evaluated on Incidence of new-onset arrhythmias. Wearable ECG monitoring for 11 days post-myocardial infarction detected paroxysmal atrial tachycardia in 56% of patients, which was associated with lower beta-blocker use (70% vs 90%, P=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: